Search Results

Study Supports Gore Flow Reversal System for Proximal Embolic Protection During Carotid Artery Stenting

January 1, 2013—In Catheterization and Cardiovascular Interventions, Horst Sievert, MD, et al published findings from a study that evaluates short- and long-term results of carotid artery stenting (CAS) with the Gore Flow Reversal System (GFRS; Gore & Associates, Flagstaff, AZ) (2013;81:133–141).

Neurotronic’s Neuviant Multiorgan Denervation Studied to Treat Type 2 Diabetes and Hypertension

November 17, 2025—Neurotronic, Inc. announced the first clinical outcomes of the NECTAR III and NECTAR IV trials evaluating the company’s Neuviant multiorgan denervation (MDN) system in patients with both type 2 diabetes mellitus (T2DM) and hypertension (HTN).

REDUCE-HTN Data Support Boston Scientific's Vessix Renal Denervation System

October 28, 2013—Boston Scientific Corporation (Natick, MA) announced that new data presented at the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California, demonstrated that patients treated with the company's Vessix renal denervation system experienced a significant and sustained reduction in blood pressure.

Interim Data From REDUCE-HTN Support Boston Scientific's Vessix Renal Denervation System

May 22, 2013—Boston Scientific Corporation (Natick, MA) announced that interim data from the REDUCE-HTN clinical program were presented at EuroPCR 2013 in Paris by Joachim Schofer, MD, of the Hamburg University Cardiovascular Center in Hamburg, Germany.

TriVascular Begins European Study of the Ovation Abdominal Stent Graft

March 22, 2010—TriVascular, Inc. (Santa Rosa, CA) announced the commencement of the European clinical study to evaluate the safety and performance of its Ovation abdominal stent graft.

TriVascular Begins European Study of the Ovation Abdominal Stent Graft

March 22, 2010—TriVascular, Inc. (Santa Rosa, CA) announced the commencement of the European clinical study to evaluate the safety and performance of its Ovation abdominal stent graft.

Vivasure Medical's PerQseal Large-Bore Closure Device Launched in Europe

November 9, 2018—Vivasure Medical Limited announced the commercial European launch of the company’s PerQseal large-bore closure device, a percutaneous vessel closure device designed for use in large-bore transcatheter procedures.

Boston Scientific Acquires Vessix Vascular

November 8, 2012—Boston Scientific Corporation (Natick, MA) has announced a definitive agreement to acquire Vessix Vascular, Inc. (Laguna Hills, CA), which developed a catheter-based renal denervation system for the treatment of uncontrolled hypertension.

Vascular Dynamics Receives Financing to Support Clinical Trials of MobiusHD Device for Heart Failure

July 12, 2022—Vascular Dynamics, Inc. (VDI), a privately held medical device company focused on endovascular device-based solutions for heart failure, announced the closing of its $20 million financing round.

Vessix Receives CE Mark Approval for V2 Renal Denervation System

May 1, 2012—Vessix Vascular, Inc. (Laguna Hills, CA) announced that it has received CE Mark approval for its V2 renal denervation system for the treatment of hypertension.